The target trial emulation study suggests rigid risk thresholds aren’t needed to steer statin use in this group.

Interventional cardiologists say some cases that coders flag and submit to the NCDR aren’t in fact problematic.

Gene-editing therapy, ACS guidelines, and the death of Dimitrios Karmpaliotis were some of TCTMD’s most-read stories this ...

Interventionalists don’t often order a CXR ahead of time, but when it’s already been done, some find the added info useful.

A steady stream of structural trial data, approvals, reimbursement decisions, and real-world rollouts arrived in 2025.

Structural heart news arrived in a steady stream throughout 2025—from pivotal trials to approvals, reimbursement decisions, ...

The year saw the emergence of a new version of an old drug that proved beneficial in patients who have heart failure with ...

The TCTMD journalists look back at the year's memorable moments—and take a few guesses at what's ahead.

Cardiovascular imaging, which continues to evolve alongside interventions and other technologies, made notable strides in the ...

Advances in the treatment of coronary artery disease remained steady in 2025, as in recent years, but the past 12 months also ...